Translational Science Research Program

Research saves lives. Strategic investment in lung cancer research will ensure patients the same promise that is now available for breast, prostate, colorectal, and other cancers — earlier detection, more effective treatment options, higher quality of life, and thousands of lives saved.

LUNGevity-funded researchers are working on finding a better way to detect, diagnose, and treat lung cancers and prevent their recurrence. We fund translational research to move knowledge as quickly as possible from basic discovery (“bench”) to treating patients (“bedside”). Funding translational research means that discoveries in the laboratory can be translated into clinical practice — to change outcomes for lung cancer patients. 

Translating research from bench to bedside

WHAT WE FUND

We are particularly interested in:

  • Finding effective biomarkers that can be used to develop a noninvasive strategy for detecting early-stage lung cancer
  • Creating more effective and efficient therapies to treat lung cancer at all stages of the disease and helping to bring these therapies to patients quickly

While we have particular interests, they do not bind us. LUNGevity welcomes innovative and novel approaches that can lead to the development of early detection and treatment practices of lung cancer.

LUNGevity projects are carefully vetted to ensure that we are funding the most impactful science possible. The review process includes a formal study section with Scientific Advisory Board members and other lung cancer experts who identify, among the grant applications we receive, the most promising proposals for research into the early detection and treatment of lung cancer. The lung cancer experts who review the grant applications assess them on a number of measures, including the likelihood that the proposed research will exert a sustained, powerful influence on the research field involved and have a near-term impact on improving lung cancer mortality rates.

print